Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.

PubWeight™: 1.09‹?› | Rank: Top 10%

🔗 View Article (PMID 16449119)

Published in Obstet Gynecol on February 01, 2006

Authors

Shalini L Kulasingam1, Evan R Myers, Herschel W Lawson, K John McConnell, Karla Kerlikowske, Joy Melnikow, A Eugene Washington, George F Sawaya

Author Affiliations

1: Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, USA. kulas002@mc.duke.edu

Articles citing this

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst (2008) 3.33

Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics (2009) 1.48

Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr (2007) 1.39

Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis (2008) 1.35

Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer (2012) 1.02

Use of electronic health record data to evaluate overuse of cervical cancer screening. J Am Med Inform Assoc (2012) 0.96

The costs of an outreach intervention for low-income women with abnormal Pap smears. Prev Chronic Dis (2006) 0.87

Ending cervical cancer screening: attitudes and beliefs from ethnically diverse older women. Am J Obstet Gynecol (2008) 0.86

Cost-Effectiveness Evaluation of Quadrivalent Human Papilloma Virus Vaccine for HPV-Related Disease in Iran. Iran J Pharm Res (2014) 0.83

Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Med (2009) 0.81

Direct human papillomavirus E6 whole-cell enzyme-linked immunosorbent assay for objective measurement of E6 oncoproteins in cytology samples. Clin Vaccine Immunol (2012) 0.79

Using simulation-optimization to construct screening strategies for cervical cancer. Health Care Manag Sci (2010) 0.75

Articles by these authors

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2007) 13.20

Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med (2014) 11.30

Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med (2003) 7.73

Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med (2007) 7.31

Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med (2004) 6.42

Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst (2002) 6.28

American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58

2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40

Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst (2006) 5.17

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09

Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81

Comparison of screening mammography in the United States and the United kingdom. JAMA (2003) 4.53

Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA (2002) 4.52

Performance benchmarks for screening mammography. Radiology (2006) 4.41

Personalizing mammography by breast density and other risk factors for breast cancer: analysis of health benefits and cost-effectiveness. Ann Intern Med (2011) 4.28

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20

Does utilization of screening mammography explain racial and ethnic differences in breast cancer? Ann Intern Med (2006) 3.95

Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology (2003) 3.90

Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med (2011) 3.83

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55

Performance of first mammography examination in women younger than 40 years. J Natl Cancer Inst (2010) 3.53

American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51

Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med (2014) 3.46

Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell (2007) 3.44

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ (2010) 3.41

American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15

Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol (2009) 3.08

Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol (2006) 3.08

2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06

Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril (2004) 3.03

Cost utility of prenatal diagnosis and the risk-based threshold. Lancet (2004) 3.00

Variability in interpretive performance at screening mammography and radiologists' characteristics associated with accuracy. Radiology (2009) 2.88

Update on the methods of the U.S. Preventive Services Task Force: insufficient evidence. Ann Intern Med (2009) 2.86

Association between mammography timing and measures of screening performance in the United States. Radiology (2005) 2.85

Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med (2012) 2.85

When radiologists perform best: the learning curve in screening mammogram interpretation. Radiology (2009) 2.78

Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med (2003) 2.72

The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis (2003) 2.72

Physician predictors of mammographic accuracy. J Natl Cancer Inst (2005) 2.72

Absence of secretory endometrium after false-positive home urine luteinizing hormone testing. Fertil Steril (2004) 2.59

A randomized comparison of total or supracervical hysterectomy: surgical complications and clinical outcomes. Obstet Gynecol (2003) 2.57

Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat (2005) 2.53

CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov (2012) 2.51

Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol (2005) 2.50

Acute myocardial infarction in pregnancy: a United States population-based study. Circulation (2006) 2.49

Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med (2015) 2.46

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42

Racial/ethnic disparities in obstetric outcomes and care: prevalence and determinants. Am J Obstet Gynecol (2010) 2.37

Concordance of breast imaging reporting and data system assessments and management recommendations in screening mammography. Radiology (2002) 2.36

Predicting the number of women who will undergo incontinence and prolapse surgery, 2010 to 2050. Am J Obstet Gynecol (2011) 2.36

Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst (2009) 2.35

Screening interval and risk of invasive squamous cell cervical cancer. Obstet Gynecol (2003) 2.19

Models in the development of clinical practice guidelines. Ann Intern Med (2014) 2.18

Volume of mammographic density and risk of breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 2.18

Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev (2013) 2.18

Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst (2009) 2.17

Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol (2013) 2.17

Which elements of improvement collaboratives are most effective? A cluster-randomized trial. Addiction (2013) 2.10

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09

Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause (2009) 2.07

Effect of breast augmentation on the accuracy of mammography and cancer characteristics. JAMA (2004) 2.07

First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants. Cancer Causes Control (2014) 2.05

Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst (2010) 2.04

Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med (2012) 1.99

Effect of hysterectomy vs medical treatment on health-related quality of life and sexual functioning: the medicine or surgery (Ms) randomized trial. JAMA (2004) 1.97

Perinatal outcomes in low-risk term pregnancies: do they differ by week of gestation? Am J Obstet Gynecol (2008) 1.95

Mammographic breast density and family history of breast cancer. J Natl Cancer Inst (2003) 1.95

Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer (2006) 1.92

Predictors of pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2009) 1.90

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA (2003) 1.89

Trends in colonoscopy for colorectal cancer screening. Med Care (2007) 1.89

Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? J Natl Cancer Inst (2013) 1.81

Influence of annual interpretive volume on screening mammography performance in the United States. Radiology (2011) 1.81

NIH consensus development conference: diagnosing gestational diabetes mellitus. NIH Consens State Sci Statements (2013) 1.81

Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst (2012) 1.80

Mammographic density and estrogen receptor status of breast cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.78

Novel use of single X-ray absorptiometry for measuring breast density. Technol Cancer Res Treat (2005) 1.78

Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Inst (2004) 1.76

Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. J Low Genit Tract Dis (2015) 1.73

Performance of diagnostic mammography for women with signs or symptoms of breast cancer. J Natl Cancer Inst (2002) 1.70

Can Medicare billing claims data be used to assess mammography utilization among women ages 65 and older? Med Care (2006) 1.70

Association between cancer risk perception and screening behavior among diverse women. Arch Intern Med (2008) 1.70

USPSTF recommendations for STI screening. Am Fam Physician (2008) 1.68

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66

Breast cancer screening among low-income or uninsured women: results from the National Breast and Cervical Cancer Early Detection Program, July 1995 to March 2002 (United States). Cancer Causes Control (2006) 1.64

HPV vaccination--more answers, more questions. N Engl J Med (2007) 1.64

Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med (2015) 1.63

MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause (2009) 1.63

Induction of labor and cesarean delivery by gestational age. Am J Obstet Gynecol (2006) 1.62

Productivity enhancement for primary care providers using multicondition care management. Am J Manag Care (2007) 1.62

Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol (2007) 1.60

Maternal ethnicity, paternal ethnicity, and parental ethnic discordance: predictors of preeclampsia. Obstet Gynecol (2005) 1.60